No requirement for V(D)J recombination in p53-deficient thymic lymphoma

Molecular and Cellular Biology

Volumn 18, Issue 6, 1998, Pages 3495-3501

  Liao, Mai Jing ^a   Zhang, Xiao Xiang ^b   Hill, Rosina ^c   Gao, Jingjin ^a   Qumsiyeh, Mazin B ^b   Nichols, Warren ^c   Van Dyke, Terry ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53; T LYMPHOCYTE RECEPTOR;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENETIC RECOMBINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINATION ACTIVATING GENE; THYMOCYTE; THYMUS LYMPHOMA; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0031869669     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.6.3495     Document Type: Article

References (46)

1. 1ck. Proc. Natl. Acad. Sci. USA 88:3977-3981.
2. Adams, J. M., and S. Cory. 1991. Transgenic models for haemopoietic malignancies. Biochim. Biophys. Acta Rev. Cancer 1072:9-31.
3. Aplan, P. D., et al. 1997. An sel gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 16:2408-2419.
4. Barlow, C., S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J. N. Crawley, T. Ried, D. Tagle, and A. Wynshaw-Boris. 1996. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86:159-171.
5. Bates, S., and K. H. Vousden. 1996. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:12-19.
6. Berns, A. 1991. Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes. J. Cell. Biochem. 47:130-135.
7. Bogue, M. A., C. Zhu, E. Aguilar-Cordova, L. A. Donehower, and D. B. Roth. 1996. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in seid mouse thymocytes. Genes Dev. 10:553-565.
8. Bosma, M., and A. Carroll. 1991. The SCID mouse mutant: definition, characterization, and potential uses. Annu. Rev. Immunol. 9:323-350.
9. Chen, J., Y. Shinkai, F. Young, and F. Alt. 1994. Probing immune functions in RAG-deficient mice. Curr. Biol. 6:313-319.
10. Chen, J., G. Tobin, J. M. Pipas, and T. A. Van Dyke. 1992. T antigen mutant activities in transgenic mice: roles of p53 and pRB-binding in tumorigenesis of the choroid plexus. Oncogene 7:1167-1175.
11. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
12. Danska, J. S., and C. J. Guidos. 1997. Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. Semin. Immunol. 9:199-206.
13. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. J. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
14. Froidevaux, S., and F. Loor. 1991. A quick procedure for identifying doubly homozygous immunodeficient seid beige mice. J. Immunol. Methods 137:275-279.
15. Guidos, C. J., C. J. Williams, I. Grandal, G. Knowles, M. T. F. Guang, and F. S. Danska. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:2038-2054.
16. Hansen, R., and M. Oren. 1997. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7:46-51.
17. Jacks, T., L. Remington, B. Williams, E. Schmitt, S. Halachmi, R. Bronson, and R. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
18. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
19. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597.
20. Kirsch, I. R., and F. Lista. 1997. Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Semin. Immunol. 9:207-215.
21. Larson, R. C., et al. 1996. Protein dimerization between Lmo2 (Rbtn2) and Tall alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15:1021-1027.
22. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
23. Liao, M.-J., et al. Unpublished data.
24. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
25. McCarthy, S. A., H. S. Symonds, and T. Van Dyke. 1994. Regulation of apoptosis in transgenic mice by SV40 T antigen-mediated inactivation of p53. Proc. Natl. Acad. Sci. USA 91:3979-3983.
26. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
27. Morgan, S. E., and M. B. Kastan. 1997. p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. 71:1-25.
28. Nacht, M., and T. Jacks. 1998. VDJ recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9:131-138.
29. Nacht, M., A. Strasser, Y. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, and T. Jacks. 1996. Mutations in the p53 and scid genes cooperate in tumorigenesis. Genes Dev. 10:2055-2065.
30. Nelson, W., and M. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1815-1823.
31. Nowell, P. C. 1997. Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Cancer Genet. Cytogenet. 94:13-19.
32. Oettinger, M. 1992. Activation of V(D)J recombination by RAG1 and RAG2. Trends Genet. 8:413-416.
33. Pipas, J. M., K. W. Peden, and D. Nathans. 1983. Mutational analysis of simian virus 40 T antigen: isolation and characterization of mutants with deletions in the T-antigen gene. Mol. Cell. Biol. 3:203-213.
34. Pircher, H., K. Burki, R. Lang, H. Hengartner, and R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559-561.
35. Qumsiyeh, M. B., and J. A. Peppers. 1996. Sensitivity and specificity of whole chromosome paint (WCP) probes are correlated with size of translocated segment. Am. J. Med. Genet. 65:173.
36. Rabbitts, T. H. 1994. Chromosomal translocations in human cancer. Nature 372:143-149.
37. Seabright, M. 1971. A rapid banding technique for human chromosomes. Lancet ii:971-972.
38. Shinkai, Y., G. Rathbun, K. Lam, E. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. Stall, and F. Alt. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855-867.
39. Symonds, H. S., S. A. McCarthy, J. Chen, J. M. Pipas, and T. Van Dyke. 1993. Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant. Mol. Cell. Biol. 13:3255-3265.
40. Taylor, A. M. R., J. A. Metcalfe, J. Thick, and Y.-F. Mak. 1996. Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438.
41. Van Dyke, T. A. 1994. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5:106.1-106.14.
42. Verma, R. S., and A. Babu. 1989. Human chromosomes: manual of basic techniques. Pergamon Press, New York, N.Y.
43. von Boehmer, H. 1990. Developmental biology of T cells in T cell-receptor transgenic mice. Annu. Rev. Immunol. 8:531-556.
44. Weaver, D. T. 1995. What to do at an end: DNA double-strand-break repair. Trends Genet. 11:388-392.
45. Westphal, C. H., S. Rowan, C. Schmaltz, A. Elson, D. E. Fisher, and P. Leder. 1997. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet. 16:396-401.
46. Xu, Y., T. Ashley, E. E. Brainerd, R. T. Bronson, M. S. Meyn, and D. Baltimore. 1996. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:2411-2422.